YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
In September 2026, Chugai Pharmaceutical reported that Roche will discontinue development of the anti-latent myostatin antibody emugrobart for obesity and return all rights, after interim Phase II data suggested clinically meaningful weigh…
Asian stock markets largely fell back Tuesday as oil prices and bond yields remain firm at relativel PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Japanese government bond yields have hit a 30‑year high, putting pressure on risk assets while pushing investors to look harder for growth themes with clear, real world use cases. Healthcare powered by artificial intelligence in Japan sits…
- Recognized for the invention of a bispecific antibody that transformed treatment paradigm through an unconventional approach – Recognized for realizing a novel drug discovery concept in which a bispecific antibody replaces the function o…
The autoimmune uveitis market is poised for steady growth, driven by the increasing recognition and diagnosis of non-infectious uveitis, the need for steroid-sparing therapies, and continued advances in targeted immunomodulatory treatments…
With governments such as China channeling fresh fiscal spending into healthcare and social security, artificial intelligence in medicine is moving from theory into real projects that need practical solutions. That creates a window for inve…
Company Logo RG-6299 targets major unmet need in IgA nephropathy with a differentiated monthly antisense therapy. Promising clinical data, global Phase III development and strong partnerships support adoption, broad geographic reach and ex…
This article first appeared on GuruFocus. Total US Net Product Sales: $161.4 million in Q2 2026, reflecting strong sequential and year-over-year growth. FILSPARI US Net Product Sales: $141.1 million, up approximately 96% year over year, dr…
SOUTH SAN FRANCISCO, Calif. and TOKYO, Aug. 4, 2026 /PRNewswire/ -- Phylo, Inc. today announced a collaboration with Chugai Pharmaceutical Co., Ltd. to deploy Biomni Lab, Phylo's agentic AI platform for biomedical research, across Chugai's…
SHANGHAI, July 21, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that the first participant has been randomized and dose…
Following a Chugai (Roche Group) collaboration with up to $250M in milestones in addition to royalties, and inspired by mammals that defy the rules of aging, Gero uses physics-first AI and human longitudinal data to develop medicines that…
The immune thrombocytopenia market is experiencing steady growth driven by increasing disease awareness and improved diagnosis rates. Advancements in targeted therapies, including thrombopoietin receptor agonists and novel immunomodulators…
Major Asian stock markets closed lower Tuesday as new US military strikes on Iran dampened optimism PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Sarepta Therapeutics is seeing lower demand for its flagship gene therapy, Elevidys, following a regulatory crackdown. Continue Reading
Sarepta Therapeutics is seeing lower demand for its flagship gene therapy, Elevidys, following a regulatory crackdown. Continue Reading
Asian stock markets largely gained ground Monday on strength in tech issues, and on media reports th PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Wondering if Chugai Pharmaceutical's share price still offers value…
TOKYO, March 30, 2026--(BUSINESS WIRE)--Mitsubishi Electric Corporation (TOKYO: 6503) announced today that the candidates for Directors, who will be proposed for election at the Ordinary General Meeting of Shareholders scheduled in June 20…
Rani Therapeutics, LLC - Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participa…
In late February 2026, Sarepta Therapeutics reported fourth‑quarter 2025 revenue of US$442.93 million and a net loss of US$412.23 million, while CEO Douglas Ingram notified the company of his plan to retire by the end of 2026 or upon appoi…
- Japan now offers ELEVIDYS gene therapy to children with Duchenne muscular dystrophy aged 3 years to less than 8 years - Company is eligible to receive a $40 million milestone payment upon first commercial sale in Japan CAMBRIDGE, Mass.,…
* Chugai Pharmaceutical press release [https://www.chugai-pharm.co.jp/english/news/detail/20260129170004_1224.html] (CHGCF [https://seekingalpha.com/symbol/CHGCF]): FY core operating profit and core net income for the fiscal year 2025 at ¥…
Rani Therapeutics, LLC SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics…
Chugai Pharmaceutical (TSE:4519) has delivered a steady annual revenue growth of nearly 5% and net income growth close to 9% recently. Investors keep a keen eye on these metrics as the healthcare landscape in Japan continues to evolve. See…
By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT On November 6th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported third quarter 2025 results. Since our last update following the announcement of the Chugai de…
Rani Therapeutics, LLC – Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics – – Completed $60.3 million oversubscribed private placement led by Samsara BioCapital with participa…
Rani Therapeutics Holdings Inc. (NASDAQ:RANI) is one of the hot stocks to buy with huge upside potential. On October 21, H.C. Wainwright analyst Brandon Folkes assumed coverage of Rani Therapeutics with a Buy rating and $11 price target. T…
Chugai Pharmaceutical (TSE:4519) reported earnings forecast to grow 8.58% per year, with revenue expected to expand at 4.7% annually, outpacing the broader Japanese market's 4.4% revenue growth. Net profit margin is solid at 32.7%, though…
TOKYO, Oct. 24, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Tokyo; Representative Director Chaiman & CEO; BT Slingsby; "Renalys") and Chugai Pharmaceutical Co., Ltd. (Headquarters: Tokyo; President & CEO: Osamu Okuda; "Chugai"…
Rani Therapeutics, LLC SAN JOSE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics…
By John Vandermosten, CFA NASDAQ:RANI READ THE FULL RANI RESEARCH REPORT With investors perched on the edge of their seats for months, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) announces a deal including upfront milestones and partner…
Apple (AAPL) Shares in Apple (AAPL) edged up just 0.3% in pre-market trading on Monday, despite fresh data indicating that early sales of its iPhone 17 series have outperformed last year’s model in China and the United States. According to…
Rani Therapeutics Holdings (RANI) has grabbed attention after announcing a collaboration and license agreement with Chugai Pharmaceutical for an oral rare disease therapy. The deal includes payments tied to development milestones as well a…
Rani Therapeutics Holdings recently announced a collaboration and license agreement with Chugai Pharmaceutical for the joint development and commercialization of an oral product combining Rani’s RaniPill oral delivery technology and Chugai…
Rani Therapeutics (RANI) said on Friday that it signed a collaboration and licensing agreement value PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Rani Therapeutics (RANI) said Friday that it has signed a collaboration and licensing deal valued at PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…